Cognitive Impairment in people living with HIV in the ART era: A Review
Tóm tắt
Từ khóa
Tài liệu tham khảo
d’Arminio Monforte, 2004, Changing incidence of central nervous system diseases in the EuroSIDA cohort, Ann Neurol, 55, 320, 10.1002/ana.10827
Morgan, 2012, Intra-individual neurocognitive variability confers risk of dependence in activities of daily living among HIV-seropositive individuals without HIV-associated neurocognitive disorders, Arch Clin Neuropsychol, 27, 293, 10.1093/arclin/acs003
Guha, 2016, Topographies of cortical and subcortical volume loss in HIV and aging in the cART era, J Acquir Immune Defic Syndr, 73, 374, 10.1097/QAI.0000000000001111
Heaton, 2011, HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors, J Neurovirol, 17, 3, 10.1007/s13365-010-0006-1
Su, 2015, Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection, AIDS, 29, 547
Woods, 2011, Prospective memory deficits are associated with unemployment in persons living with HIV infection, Rehabil Psychol, 56, 77, 10.1037/a0022753
Gorman, 2009, Functional consequences of HIV-associated neuropsychological impairment, Neuropsychol Rev, 19, 186, 10.1007/s11065-009-9095-0
Emlet, 2006, An examination of the social networks and social isolation in older and younger adults living with HIV/AIDS, Health Soc Work, 31, 299, 10.1093/hsw/31.4.299
Antinori, 2007, Updated research nosology for HIV-associated neurocognitive disorders, Neurology, 69, 1789, 10.1212/01.WNL.0000287431.88658.8b
Heaton, 2010, HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study, Neurology, 75, 2087, 10.1212/WNL.0b013e318200d727
Nightingale, 2014, Controversies in HIV-associated neurocognitive disorders, Lancet Neurol, 13, 1139, 10.1016/S1474-4422(14)70137-1
Gisslén, 2011, The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?, BMC Infect Dis, 11, 356, 10.1186/1471-2334-11-356
De Francesco, 2016, Defining cognitive impairment in people-living-with-HIV: the POPPY study, BMC Infect Dis, 16, 617, 10.1186/s12879-016-1970-8
Sacktor, 2016, Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study, Neurology, 86, 334, 10.1212/WNL.0000000000002277
O’connor, 2018, Brain structural changes following HIV Infection: meta-analysis, AJNR Am J Neuroradiol, 39, 54, 10.3174/ajnr.A5432
Hagberg, 2010, Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection, AIDS Res Ther, 7, 15, 10.1186/1742-6405-7-15
Jessen Krut, 2014, Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients, PLoS One, 9, e88591, 10.1371/journal.pone.0088591
Association, B.H., 2013
Vance, 2014, An overview of the biological and psychosocial context surrounding neurocognition in HIV, J Am Psychiatr Nurses Assoc, 20, 117, 10.1177/1078390314527549
Cody, 2016, The neurobiology of HIV and its impact on cognitive reserve: a review of cognitive interventions for an aging population, Neurobiol Dis, 92, 144, 10.1016/j.nbd.2016.01.011
Fabbiani, 2013, Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients, HIV Med, 14, 136, 10.1111/j.1468-1293.2012.01044.x
Nightingale, 2017, Measuring and managing cognitive impairment in HIV, AIDS, 31, S165, 10.1097/QAD.0000000000001402
Valcour, 2011, Pathogenesis of HIV in the central nervous system, Curr HIV/AIDS Rep, 8, 54, 10.1007/s11904-010-0070-4
Calcagno, 2018, CNS-targeted antiretroviral strategies: when are they needed and what to choose, Curr HIV/AIDS Rep, 15, 84
Wright, 2015, Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial, HIV Med, 16, 97, 10.1111/hiv.12238
Winston, 2014, Can antiretroviral therapy prevent HIV-associated cognitive disorders?, Curr Opin HIV AIDS, 9, 11, 10.1097/COH.0000000000000016
Chan, 2016, Cognitive impairment and persistent CNS injury in treated HIV, Curr HIV/AIDS Rep, 13, 209, 10.1007/s11904-016-0319-7
Edén, 2010, HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment, J Infect Dis, 202, 1819, 10.1086/657342
Canestri, 2010, Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy, Clin Infect Dis, 50, 773, 10.1086/650538
Di Carlofelice, 2018, Cerebrospinal fluid HIV RNA in persons living with HIV, HIV Med, 19, 365, 10.1111/hiv.12594
Bednar, 2015, Compartmentalization, viral evolution, and viral latency of HIV in the CNS, Curr HIV/AIDS Rep, 12, 262, 10.1007/s11904-015-0265-9
Underwood, 2015, Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?, AIDS, 29, 253, 10.1097/QAD.0000000000000538
Letendre, 2014, ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects, Clin Infect Dis, 59, 1032, 10.1093/cid/ciu477
Ellis, 2014, Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder, Clin Infect Dis, 58, 1015, 10.1093/cid/cit921
Marra, 2009, Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance, AIDS, 23, 1359, 10.1097/QAD.0b013e32832c4152
Fischer-Smith, 2008, Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies, J Neurovirol, 14, 318, 10.1080/13550280802132857
Schuenke, 2003, Human microglial cell isolation from adult autopsy brain: brain pH, regional variation, and infection with human immunodeficiency virus type 1, J Neurovirol, 9, 346, 10.1080/13550280390201056
Churchill, 2009, Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia, Ann Neurol, 66, 253, 10.1002/ana.21697
Saylor, 2016, HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment, Nat Rev Neurol, 12, 234, 10.1038/nrneurol.2016.27
Wada, 2015, The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation, AIDS, 29, 463, 10.1097/QAD.0000000000000545
Vera, 2016, Neuroinflammation in treated HIV-positive individuals: a TSPO PET study, Neurology, 86, 1425, 10.1212/WNL.0000000000002485
Jawaid, 2011, Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons, Neurology, 77, 406, 10.1212/WNL.0b013e3182246ffb
Samaras, 2007, Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia, Diabetes Care, 30, 113, 10.2337/dc06-1075
Wallace, 1997, Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted disease history, Sex Transm Dis, 24, 398, 10.1097/00007435-199708000-00003
Duprez, 2012, Inflammation, coagulation and cardiovascular disease in HIV-infected individuals, PLoS One, 7, e44454, 10.1371/journal.pone.0044454
Nanni, 2015, Depression in HIV infected patients: a review, Curr Psychiatry Rep, 17, 530, 10.1007/s11920-014-0530-4
Watkins, 2011, Safety considerations in drug treatment of depression in HIV-positive patients: an updated review, Drug Saf, 34, 623, 10.2165/11592070-000000000-00000
De Francesco, 2016
Wang, 2014, White matter abnormalities in medication-naïve adult patients with major depressive disorder: tract-based spatial statistical analysis, Neuro Endocrinol Lett, 35, 697
Everall, 2006, Diminished somatostatin gene expression in individuals with HIV and major depressive disorder, Neurology, 67, 1867, 10.1212/01.wnl.0000244436.04036.a2
Schroecksnadel, 2008, Quality of life and immune activation in patients with HIV-infection, Brain Behav Immun, 22, 881, 10.1016/j.bbi.2007.12.011
Gonzalez, 2011, Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis, J Acquir Immune Defic Syndr, 58, 181, 10.1097/QAI.0B013E31822D490A
Ferrando, 2008, Treatment of depression in HIV positive individuals: a critical review, Int Rev Psychiatry, 20, 61, 10.1080/09540260701862060
Rabkin, 1994, Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness, Am J Psychiatry, 151, 516, 10.1176/ajp.151.4.516
Rabkin, 1994, Effects of fluoxetine on mood and immune status in depressed patients with HIV illness, J Clin Psychiatry, 55, 92
Watkins, 2015, Cognitive impairment in patients with AIDS - prevalence and severity, HIV AIDS (Auckl), 7, 35
Cysique, 2014, The effects of HIV and aging on brain functions: proposing a research framework and update on last 3 years’ findings, Curr Opin HIV AIDS, 9, 355, 10.1097/COH.0000000000000078
Sacktor, 2010, Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus, J Neurovirol, 16, 335, 10.3109/13550284.2010.504249
Pfefferbaum, 2014, Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study, Neurobiol Aging, 35, 1755, 10.1016/j.neurobiolaging.2014.01.008
Haynes, 2018, HIV: ageing, cognition and neuroimaging at 4-year follow-up, HIV Med, 10.1111/hiv.12598
Cole, 2017, Increased brain-predicted aging in treated HIV disease, Neurology, 88, 1349, 10.1212/WNL.0000000000003790
Cole, 2018, No evidence for accelerated ageing-related brain pathology in treated HIV: longitudinal neuroimaging results from the Comorbidity in Relation to AIDS (COBRA) project, Clin Infect Dis, 10.1093/cid/cix1124
Turner, 2016, An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition, Alzheimers Dement (Amst), 4, 1, 10.1016/j.dadm.2016.03.009
Cooley, 2016, Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals, J Neurovirol, 22, 607, 10.1007/s13365-016-0434-7
Becker, 2015, No association between Apoε4 alleles, HIV infection, age, neuropsychological outcome, or death, J Neurovirol, 21, 24, 10.1007/s13365-014-0290-2
Cysique, 2015, APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study, BMC Neurol, 15, 51, 10.1186/s12883-015-0298-0
Giunta, 2011, Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders, Mol Brain, 4, 23, 10.1186/1756-6606-4-23
András, 2013, Amyloid beta accumulation in HIV-1-infected brain: the role of the blood brain barrier, IUBMB Life, 65, 43, 10.1002/iub.1106
Ances, 2012, 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder, Arch Neurol, 69, 72, 10.1001/archneurol.2011.761
Gisslén, 2016, Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study, EBioMedicine, 3, 135, 10.1016/j.ebiom.2015.11.036
Clifford, 2017, HIV-associated neurocognitive disorder, Curr Opin Infect Dis, 30, 117, 10.1097/QCO.0000000000000328